Plazomicin may be well-suited to play a critical role in biodefense preparedness --Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Achaogen (AKAO) Prices 15M Share Common Offering at $1/ShFebruary 15, 2019 6:15 AM Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShieldFebruary 14, 2019 8:30 AM